Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
Gilead Sciences Inc said on Friday additional data from a late-stage study revealed its antibacterial remdesivir significantly enhanced clinical recovery from seriously ill COVID-19 patients.
Findings from a study of its late-stage study revealed that 74.4 percent of remdesivir-treated patients recovered by Day 14 versus 59.0 percentage of individuals receiving standard of care, the business said.
Gilead shares were up almost 2 percent 76.14 prior to the bell.